MY142046A - Rapid dissolution formulation of a calcium receptor-active compound - Google Patents

Rapid dissolution formulation of a calcium receptor-active compound

Info

Publication number
MY142046A
MY142046A MYPI20043684A MYPI20043684A MY142046A MY 142046 A MY142046 A MY 142046A MY PI20043684 A MYPI20043684 A MY PI20043684A MY PI20043684 A MYPI20043684 A MY PI20043684A MY 142046 A MY142046 A MY 142046A
Authority
MY
Malaysia
Prior art keywords
active compound
calcium receptor
rapid dissolution
dissolution formulation
pharmaceutical composition
Prior art date
Application number
MYPI20043684A
Inventor
Francisco J Alvarez
Hung-Ren H Lin
Glen Gary Lawrence
Tzuchi R Ju
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY142046(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MY142046A publication Critical patent/MY142046A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Abstract

THE PRESENT INVENTION RELATES TO A PHARMACEUTICAL COMPOSITION COMPRISING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A CALCIUM RECEPTOR-ACTIVE COMPOUND AND AT LEAST ONE PHARMACEAUTICALLY ACCEPTABLE EXCIPIENT, WHEREIN THE COMPOSITION HAS A CONTROLLED DISSOLUTION PROFILE. THE PRESENT INVENTION FURTHER RELATES TO A METHOD OF MANUFACTURING THE PHARMACEUTICAL COMPOSITION, AS WELL AS METHOD OF TREATING A DISEASE USING THE PHARMACEUTICAL COMPOSITION.
MYPI20043684A 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound MY142046A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12

Publications (1)

Publication Number Publication Date
MY142046A true MY142046A (en) 2010-08-30

Family

ID=34434844

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20043684A MY142046A (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound

Country Status (30)

Country Link
US (7) US7829595B2 (en)
EP (8) EP2316442A1 (en)
JP (3) JP5026077B2 (en)
KR (1) KR101332058B1 (en)
CN (1) CN1946382B (en)
AR (1) AR045637A1 (en)
AU (1) AU2004279318C1 (en)
BR (2) BR122018013029B1 (en)
CA (1) CA2536487C (en)
CY (5) CY1119609T1 (en)
DE (1) DE19164145T1 (en)
DK (6) DK3260117T3 (en)
EA (1) EA013425B1 (en)
ES (7) ES2812198T1 (en)
HR (1) HRP20130114T4 (en)
HU (5) HUE044279T2 (en)
IL (1) IL173737A (en)
IS (1) IS3027B (en)
MX (1) MXPA06002616A (en)
MY (1) MY142046A (en)
NO (1) NO335739B1 (en)
NZ (1) NZ545498A (en)
PL (6) PL1663182T5 (en)
PT (6) PT2821067T (en)
SG (1) SG146608A1 (en)
SI (6) SI2821067T1 (en)
TR (4) TR201909267T4 (en)
TW (1) TWI344363B (en)
WO (1) WO2005034928A1 (en)
ZA (1) ZA200602710B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SI2821067T1 (en) 2003-09-12 2018-03-30 Amgen Inc. Rapid dissolution formulation of cinacalcet
HUE032540T2 (en) 2004-06-24 2017-09-28 Vertex Pharma Modulators of ATP-binding cassette transporters
CA2603145A1 (en) * 2005-05-16 2006-11-23 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet hydrochloride
MX2007000983A (en) * 2005-05-23 2007-04-16 Teva Pharma Processes for preparing cinacalcet hydrochloride crystal form i.
EP1883625A2 (en) * 2005-05-23 2008-02-06 Teva Pharmaceutical Industries Ltd Amorphous cinacalcet hydrochloride and preparation thereof
AU2006250340C1 (en) 2005-05-26 2014-06-12 Sumitomo Pharma Co., Ltd. Pharmaceutical composition
JP5244597B2 (en) * 2005-09-02 2013-07-24 アムジエン・インコーポレーテツド Method for regulating intestinal fluid balance using calcilytic or calcimimetic compounds
WO2007062147A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation
PL1993360T3 (en) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
ES2904546T3 (en) 2006-02-03 2022-04-05 Opko Renal Llc Treatment of vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
AU2007230724B2 (en) * 2006-03-23 2014-01-30 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
US7449603B2 (en) * 2006-04-27 2008-11-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
MX2008000140A (en) * 2006-04-27 2009-02-23 Teva Pharma Process for the preparation of cinacalcet base.
WO2008008608A2 (en) 2006-06-21 2008-01-17 Proventiv Therapeutics, Llc Method of treating and preventing secondary hyperparathyroidism
EP2069285A1 (en) * 2006-06-27 2009-06-17 Sandoz AG Amorphous form of cinacalcet
CA2662315A1 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Solid composites of a calcium receptor-active compound
WO2008063645A1 (en) * 2006-11-20 2008-05-29 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
TW201718635A (en) 2007-03-06 2017-06-01 安美基公司 Variant activin receptor polypeptides and uses thereof
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
JP5444212B2 (en) 2007-04-25 2014-03-19 シトクロマ インコーポレイテッド Method for treating vitamin D deficiency and deficiency
PL2148661T3 (en) 2007-04-25 2013-07-31 Cytochroma Inc Oral controlled release compositions comprising vitamin d compound and waxy carrier
WO2009002427A2 (en) * 2007-06-21 2008-12-31 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
WO2010071689A2 (en) * 2008-05-05 2010-06-24 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl]-1-aminopropane derivative
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010034497A2 (en) 2008-09-25 2010-04-01 Ratiopharm Gmbh Compacted cinacalcet
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
WO2010108162A1 (en) 2009-03-20 2010-09-23 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
CA2762137A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
CA2762130A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (en) 2009-10-21 2011-04-27 Ratiopharm GmbH Melt granulated cinacalcet
ES2783980T3 (en) 2010-03-29 2020-09-21 Opko Ireland Global Holdings Ltd Methods and compositions for the reduction of parathyroid levels
EP2603215A4 (en) 2010-08-11 2015-08-05 Philadelphia Health & Educatio Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
CA2818565A1 (en) * 2010-11-23 2012-05-31 Amgen Inc. Pediatric formulation
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
JP2014507375A (en) 2010-11-26 2014-03-27 レオ ファーマ アクティーゼルスカブ Calcium-sensing receptor active compound
US20130244995A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
SG11201403367YA (en) 2011-12-19 2014-07-30 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP2804588B1 (en) 2012-01-17 2017-09-06 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
US20130224293A1 (en) 2012-02-27 2013-08-29 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
CN102885792A (en) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 Oral solid rapid release preparation of cinacalcet hydrochloride
EP2730279B1 (en) 2012-11-09 2015-07-22 K.H.S. Pharma Holding GmbH Immediate release formulations of cinacalcet
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
BR112015014430B1 (en) * 2012-12-21 2022-08-30 Synthon B.V. TABLET COMPOSITION
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
US10016374B2 (en) * 2013-06-26 2018-07-10 Jubilant Generics Limited Disintegrant free composition of Cinacalcet
EP3116487A1 (en) * 2014-03-14 2017-01-18 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
SG11201700858RA (en) 2014-08-07 2017-03-30 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
JP6746569B2 (en) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104721164B (en) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 A kind of cinacalcet hydrochloride Film coated tablets composition
TWI747893B (en) 2016-03-28 2021-12-01 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 Methods of vitamin d treatment
CN109152787A (en) 2016-03-31 2019-01-04 英特塞普特医药品公司 Oral preparation with superior stripping property
US11331283B2 (en) * 2017-08-16 2022-05-17 Unichem Laboratories Ltd Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders
EP3773533A1 (en) 2018-03-30 2021-02-17 FTF Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (en) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Cinacalcet hydrochloride tablet core
EP4110304A1 (en) * 2020-02-29 2023-01-04 KemPharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
CN112546010A (en) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 Pharmaceutical composition for treating nephropathy and preparation method thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
EP0315249A1 (en) 1987-11-02 1989-05-10 Merck & Co. Inc. Phthalazineacetic acid composition and tablet
EP0357815A1 (en) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Switchable constant current source for I2L gates
IL92484A0 (en) 1988-11-30 1990-08-31 Schering Corp Sustained release diltiazem formulation
NZ231897A (en) 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (en) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch METHOD AND DEVICE FOR FINE CLEANING OF TEXTILE FIBERS
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
WO1995011221A1 (en) 1991-08-23 1995-04-27 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
RU2147574C1 (en) 1991-08-23 2000-04-20 Эн-Пи-Эс Фармасьютикалз, Инк. Arylalkylamines, compositions, methods of treatment and diagnosis, method of identification of compound
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP4143118B2 (en) 1993-02-23 2008-09-03 ブリガム・アンド・ウイミンズ・ホスピタル・インコーポレイテッド Calcium receptor activating molecule and related substances
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
PL181304B1 (en) * 1994-07-22 2001-07-31 Lilly Co Eli Combined osteoporosis inhibiting treatment
EP1553078A1 (en) * 1994-10-21 2005-07-13 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (en) 1995-08-19 1997-02-20 Gruenenthal Gmbh Rapidly disintegrating drug form of tramadol or a tramadol salt
DK0907631T3 (en) 1996-05-01 2003-09-22 Nps Pharma Inc Inorganic ion receptor active compounds
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
KR100771092B1 (en) 1996-07-08 2007-10-30 기린 파마 가부시끼가이샤 Calcium Receptor-Active Compounds
DE19637082A1 (en) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Rapidly disintegrating pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (en) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Printer or copier system for performance-adapted creation of a predetermined sheet series of monochrome and/or colour printed individual sheets
AU741992B2 (en) 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
WO2000021910A2 (en) 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
BR9915566B1 (en) 1998-11-23 2011-11-01 herbicidal composition and herbicidal process.
UA74141C2 (en) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (en) 1999-11-09 2002-02-01 Centre Nat Rech Scient NOVEL ARALKYL-1,2-DIAMINES HAVING CALCIMIMETIC ACTIVITY AND THEIR METHOD OF PREPARATION
AU2731401A (en) 1999-12-22 2001-07-03 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU5066101A (en) 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (en) 2000-05-24 2005-10-14 Centre Nat Rech Scient NOVEL MOLECULES HAVING CALCIMIMETIC ACTIVITY AND THEIR METHOD OF PREPARATION
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
JP2002167327A (en) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd Solid formulation
AU2001288102A1 (en) 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (en) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
ATE361758T1 (en) 2001-06-22 2007-06-15 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A MEDICINE THAT IS POORLY SOLUBLE IN WATER AND A SOLUBILITY-INCREASE POLYMER
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
WO2003086343A2 (en) 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
AU2003272767A1 (en) 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
SI2821067T1 (en) 2003-09-12 2018-03-30 Amgen Inc. Rapid dissolution formulation of cinacalcet
DE202005021414U1 (en) 2004-08-23 2008-03-20 Teva Pharmaceutical Industries Ltd. Solid and crystalline ibandronate sodium
NL1028867C2 (en) 2005-04-26 2006-10-27 Xycarb Ceramics B V Device for supporting a substrate and a method for manufacturing such a device.
WO2009111876A1 (en) 2008-03-11 2009-09-17 The University Of Western Ontario System and method for magnetic resonance imaging

Also Published As

Publication number Publication date
TR201910180T4 (en) 2019-07-22
NO335739B1 (en) 2015-02-02
EP3260117B8 (en) 2019-11-27
EP3395340B8 (en) 2019-12-11
IS3027B (en) 2021-03-15
JP2007505108A (en) 2007-03-08
CA2536487C (en) 2011-10-25
EP3395339A1 (en) 2018-10-31
DE19164145T1 (en) 2021-04-29
CY1121812T1 (en) 2020-07-31
US20210052518A1 (en) 2021-02-25
PT3260117T (en) 2019-07-04
HUE045411T2 (en) 2019-12-30
JP5940120B2 (en) 2016-06-29
CN1946382B (en) 2010-12-08
PT3395338T (en) 2019-07-23
ES2734057T3 (en) 2019-12-04
AU2004279318B2 (en) 2010-02-25
PL3395340T3 (en) 2019-10-31
EP3395340B1 (en) 2019-04-17
SI1663182T2 (en) 2020-02-28
IS8324A (en) 2006-02-23
EP3260117B1 (en) 2019-04-17
PT3395339T (en) 2019-07-15
EP3578175B1 (en) 2022-11-30
TR201910177T4 (en) 2019-08-21
SI3395339T1 (en) 2019-08-30
ES2812198T1 (en) 2021-03-16
HUE035596T2 (en) 2018-05-28
EP2316442A1 (en) 2011-05-04
IL173737A0 (en) 2006-07-05
SI3395340T1 (en) 2019-08-30
TW200518743A (en) 2005-06-16
BR122018013029B1 (en) 2022-04-12
US20110136915A1 (en) 2011-06-09
HUE044279T2 (en) 2019-10-28
US20180243238A1 (en) 2018-08-30
DK1663182T3 (en) 2013-04-15
DK3395338T3 (en) 2019-07-22
EP3395340A1 (en) 2018-10-31
CA2536487A1 (en) 2005-04-21
TR201909267T4 (en) 2019-07-22
SI3395338T1 (en) 2019-08-30
AU2004279318A1 (en) 2005-04-21
SI2821067T1 (en) 2018-03-30
US20190117592A1 (en) 2019-04-25
AU2004279318C1 (en) 2020-06-25
DK2821067T3 (en) 2017-12-04
HRP20130114T1 (en) 2013-03-31
EA200600566A1 (en) 2006-08-25
PT3395340T (en) 2019-07-15
US9375405B2 (en) 2016-06-28
IL173737A (en) 2012-04-30
US7829595B2 (en) 2010-11-09
JP2015007089A (en) 2015-01-15
EP3395339B8 (en) 2019-12-11
BRPI0414254B8 (en) 2021-05-25
PL2821067T3 (en) 2018-02-28
DK3395339T3 (en) 2019-07-22
EP3395338B1 (en) 2019-05-01
KR101332058B1 (en) 2013-11-22
MXPA06002616A (en) 2006-06-05
HRP20130114T4 (en) 2019-12-27
HUE043958T2 (en) 2019-09-30
ES2737348T3 (en) 2020-01-13
CY1121814T1 (en) 2020-07-31
CY1119609T1 (en) 2018-04-04
SI1663182T1 (en) 2013-05-31
CY1121820T1 (en) 2020-07-31
ES2401769T5 (en) 2020-07-01
US20160338975A1 (en) 2016-11-24
US20050147669A1 (en) 2005-07-07
BRPI0414254A (en) 2006-11-07
PT1663182E (en) 2013-03-14
EA013425B1 (en) 2010-04-30
CY1122259T1 (en) 2020-11-25
ES2401769T3 (en) 2013-04-24
JP2012197280A (en) 2012-10-18
DK3260117T3 (en) 2019-07-01
ZA200602710B (en) 2007-04-25
EP1663182A1 (en) 2006-06-07
EP3395339B1 (en) 2019-04-17
EP1663182B2 (en) 2019-11-20
JP5849015B2 (en) 2016-01-27
US20200222340A1 (en) 2020-07-16
PL3395339T3 (en) 2019-09-30
EP3395338A1 (en) 2018-10-31
PL3260117T3 (en) 2019-10-31
TWI344363B (en) 2011-07-01
JP5026077B2 (en) 2012-09-12
TR201910447T4 (en) 2019-08-21
PL1663182T5 (en) 2020-07-27
DK3395340T3 (en) 2019-07-15
AR045637A1 (en) 2005-11-02
BRPI0414254B1 (en) 2021-03-02
NO20061640L (en) 2006-06-12
ES2655435T3 (en) 2018-02-20
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
PL1663182T3 (en) 2013-06-28
NZ545498A (en) 2010-04-30
PL3395338T3 (en) 2019-10-31
EP3260117A1 (en) 2017-12-27
HUE044822T2 (en) 2019-11-28
CN1946382A (en) 2007-04-11
WO2005034928A1 (en) 2005-04-21
KR20070017460A (en) 2007-02-12
ES2735226T3 (en) 2019-12-17
EP2821067A1 (en) 2015-01-07
PT2821067T (en) 2017-12-01
DK1663182T4 (en) 2020-02-17
ES2735216T3 (en) 2019-12-17
EP2821067B1 (en) 2017-10-25
SG146608A1 (en) 2008-10-30
SI3260117T1 (en) 2019-08-30

Similar Documents

Publication Publication Date Title
MY142046A (en) Rapid dissolution formulation of a calcium receptor-active compound
ZA200501082B (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
WO2004037773A8 (en) Phenethanolamine derivative for the treatment of respiratory diseases
BRPI0415288A (en) compound, pharmaceutical composition, method for treating or preventing disease, and method for preparing the compound
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
WO2002014311A3 (en) Urea compounds and methods of uses
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
IL193252A0 (en) N-hydroxyacrylamide compounds
BRPI0517032A (en) compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treating and / or preventing diseases and using such compounds
WO2006058720A3 (en) Novel compounds for the treatment of neurological disorders
PL371205A1 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
BR0315462A (en) Compound, pharmaceutical composition, use of a compound, method for treating a subject suffering from a pathological condition or disease susceptible to ltd4 receptor antagonism and combination product
HK1091816A1 (en) Diphenylurea derivatives and their use as chloride channel blockers
PL373553A1 (en) Salt of morphine-6-glucuronide
MXPA01009032A (en) Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12-production.
DE60102084D1 (en) PROPANOLAMINOTETRALINES, METHOD FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
ECSP055700A (en) USE OF DERIVATIVES OF 4-PIRIDIL-METHYL-FTALAZINE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF MYELODISPLASTIC SYNDROMES
WO2003011309A3 (en) Pharmaceutical composition for treating hypercholesterolaemia
GR1004660B (en) Advanced alendronate sodium trihydrate pharmaceutical compositions and preparation methods thereof
CY1113703T1 (en) SHORT SOLUTION PHARMACEUTICAL FORM OF SINAKALSET HCI
MXPA04001951A (en) Coniosulphides and their derivatives, method for their production and use as medicaments.
MXPA05003633A (en) 2" oxo-voruscharin and derivatives thereof.
EP1408043A8 (en) 2''oxo-voruscharin and analogues thereof